Novocure Ltd (NVCR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Novocure Ltd stock (NVCR) is currently trading at $11.61. Novocure Ltd PS ratio (Price-to-Sales) is 1.97. Analyst consensus price target for NVCR is $25.93. WallStSmart rates NVCR as Sell.
- NVCR PE ratio analysis and historical PE chart
- NVCR PS ratio (Price-to-Sales) history and trend
- NVCR intrinsic value — DCF, Graham Number, EPV models
- NVCR stock price prediction 2025 2026 2027 2028 2029 2030
- NVCR fair value vs current price
- NVCR insider transactions and insider buying
- Is NVCR undervalued or overvalued?
- Novocure Ltd financial analysis — revenue, earnings, cash flow
- NVCR Piotroski F-Score and Altman Z-Score
- NVCR analyst price target and Smart Rating
Novocure
📊 No data available
Try selecting a different time range
Smart Analysis
Novocure Ltd (NVCR) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Novocure Ltd (NVCR) Key Strengths (2)
86.05% of shares held by major funds and institutions
Paying $1.97 for every $1 of annual revenue
Supporting Valuation Data
Novocure Ltd (NVCR) Areas to Watch (8)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Earnings declining -6.00%, profits shrinking
Company is losing money with a negative profit margin
Premium pricing at 3.9x book value
Modest revenue growth at 8.10%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Novocure Ltd (NVCR) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.0/10) while 8 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales. Valuation metrics including Price/Sales (1.97) suggest the stock is attractively priced.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Book (3.95) suggest expensive pricing. Growth concerns include Revenue Growth at 8.10%, EPS Growth at -6.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -38.90%, Operating Margin at -21.30%, Profit Margin at -20.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -38.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NVCR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NVCR's Price-to-Sales ratio of 1.97x trades at a deep discount to its historical average of 15.6x (0th percentile). The current valuation is 98% below its historical high of 84.31x set in Nov 2015, and 0% above its historical low of 1.97x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Novocure Ltd (NVCR) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Novocure Ltd is in a turnaround phase, with management focused on restoring profitability. Revenue reached 655M with 8% growth year-over-year. The company is currently unprofitable, posting a -20.8% profit margin.
Key Findings
The company is unprofitable with a -20.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -23M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Novocure Ltd.
Bottom Line
Novocure Ltd is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Novocure Ltd(NVCR)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.